Connect with us

Australia

Arafura Resources poised to progress Nolans NdPr Project development

Arafura Resources Limited (ASX:ARU) has reached several milestones needed to progress the development of its Nolans Neodymium-Praseodymium (NdPr) Project in the Northern Territory.

These include Major Project Status (MPS) renewal from the Australian Government, mineral leases granted from the NT Government, the signing of the Native Title Agreement plus the completion of a $7 million placement to fund project development.

The company is ready to commence project development once offtake and funding have been secured.

Major project status[hhmc]
The company recently secured MPS renewal from the Australian Government for another three years.

This acknowledges Nolans as a strategically significant Australian critical minerals and advanced materials development project and provides access to a range of Australian Government services and programs.

The MPS allows a single entry point for a range of Australian Government coordination services, including helping to map out the projects com..

Arafura Resources Limited (ASX:ARU) has reached several milestones needed to progress the development of its Nolans Neodymium-Praseodymium (NdPr) Project in the Northern Territory.

These include Major Project Status (MPS) renewal from the Australian Government, mineral leases granted from the NT Government, the signing of the Native Title Agreement plus the completion of a $7 million placement to fund project development.

The company is ready to commence project development once offtake and funding have been secured.

Major project status


The company recently secured MPS renewal from the Australian Government for another three years.

This acknowledges Nolans as a strategically significant Australian critical minerals and advanced materials development project and provides access to a range of Australian Government services and programs.

The MPS allows a single entry point for a range of Australian Government coordination services, including helping to map out the projects commercial compliance obligations and assisting with identifying suitable government employment and training programs that supports Arafuras efforts in delivering jobs and investment opportunities to Central Australia.

Supporting the NT economy


The Australian Governments renewal of MPS coincides with the grant of Arafuras cornerstone development tenure at Nolans and the companys formal submission to the Territory Economic Reconstruction Commission which is tasked with developing strategies to accelerate the progress of investment-ready long-life critical minerals projects like Nolans as an engine for economic growth of the Northern Territory.

The project represents a unique opportunity for Australia to diversify the rare earths supply chain, increase advanced materials manufacturing and potentially seed new high technology downstream industries from one of the worlds safest and most secure jurisdictions.

Arafura is positioned to play a key role in addressing the fragile nature of or gaps in critical minerals supply chains that have been brought into greater focus by commercial disruptions caused by international trade tensions and COVID-19.

Mineral leases granted


Arafura also jumped the final regulatory hurdle for the project with the granting of mineral leases (MLs) by the NT Government.

This key milestone secures the Nolans Bore mineral resource for an initial period of 25 years.

The MLs, which will host the Nolans mine, process plant, waste storage facilities and accommodation village, were granted to Arafuras wholly-owned subsidiary Arafura Rare Earths Pty Ltd (ARE) by Northern Territory Minister for Primary Industry and Resources Paul Kirby.

Nolans Project location

Native Title Agreement


This comes after the signing of the projects Native Title Agreement (NTA) last month by Anmatyerr native title holders and Central Land Council (CLC) who, in so doing, gave their consent to the grant of all the MLs allowing for multiple renewals beyond the initial grant term.

The grant process provides Arafura with the exclusive right to mine and to occupy the primary mineral lease, ML 26659, ancillary mineral leases, MLs 30702 to 30704, 32411 to 32416 and related access authorities.

These mineral leases host the mine, process plant, tailings and process residues containment facilities, accommodation village, borefield and the infrastructure elements of the Nolans operation.

Under the terms of the Native Title Agreement:

  • Arafura personnel who work at the operation will undergo cultural awareness induction and training;
  • Arafura commits to provide employment and training as well as business opportunities for the native title holders and local Aboriginal people to win contract work from ARE;
  • ARE acknowledges its environmental commitments and responsibilities and its duty to protect sacred sites and sacred objects; and
  • ARE agrees to processes and information sharing to ensure its agreed commitments are met.

The Native Title Agreement also pRead More – Source

Continue Reading

Australia

THC Global plans to accelerate medicinal cannabis production on back of strong June quarter

THC Global Group Ltd (ASX:THC) reached several milestones in the June quarter, supplying its first Australian patient with Canndeo branded medicinal cannabis medicines produced at its Southport Facility.

The roll-out of the full suite of the Canndeo medicines range is continuing throughout this quarter and will see the launch of eight new medicine formulations for Australian patients.

THC is also preparing for its maiden export of Canndeo branded medicines to Europe and Canada, with supply expected to commence in quarter three for Canada and quarter four for Europe.

New Zealand exports[hhmc]
In addition to medicinal cannabis sales under the Canndeo brand, THC is now a manufacturer for both Cannatrek and Medleaf Therapeutics.

Under the agreements with Cannatrek and Medleaf, THC will produce and white-label cannabis medicines under those respective brands for sale in the Australian and New Zealand market.

The initial export order to New Zealand worth $260,000 is expected to be deliv..

THC Global Group Ltd (ASX:THC) reached several milestones in the June quarter, supplying its first Australian patient with Canndeo branded medicinal cannabis medicines produced at its Southport Facility.

The roll-out of the full suite of the Canndeo medicines range is continuing throughout this quarter and will see the launch of eight new medicine formulations for Australian patients.

THC is also preparing for its maiden export of Canndeo branded medicines to Europe and Canada, with supply expected to commence in quarter three for Canada and quarter four for Europe.

New Zealand exports


In addition to medicinal cannabis sales under the Canndeo brand, THC is now a manufacturer for both Cannatrek and Medleaf Therapeutics.

Under the agreements with Cannatrek and Medleaf, THC will produce and white-label cannabis medicines under those respective brands for sale in the Australian and New Zealand market.

The initial export order to New Zealand worth $260,000 is expected to be delivered by the company in October.

Tetra Health


The Companys newly acquired clinic network, Tetra Health, has seen significant growth since acquisition with an increase of over 30% in patient enquiries in June alone.

Tetra Health is a key strategic asset for the company in seeking to bridge the affordability gap for cannabis medicines in Australia by providing low cost of access for new patients and product-independent guidance on medicines.

Hydroponics equipment


As announced in early July, the companys hydroponics equipment and cultivation solutions provider achieved its maiden $3 million unaudited half-year trading revenue milestone in June 2020, with total first half 2020 unaudited revenue reaching $3.2 million, being around a 50% increase over the prior period.

The launch of new product and service offerings targeted at the micro-cultivator and home-cultivator sectors through the year is expected to drive further revenue growth.

Difficulties in sourcing and transporting of merchandise from major Asian manufacturing hubs experienced in quarter one due to COVID-19 appear to have partially subsided over quarter two.

As the company noted in its quarter one update, these delays have affected the timing of cash receipts from customers but is unlikely to significantly affect revenue over a longer time scale given pending customer orders are fulfilled as stock is landed in Canada.

THC is preparing for its maiden export of Canndeo branded medicines to Europe and Canada

$8.1 million capital raising


During the quarter, the company completed an institutional placement to raise $6.6 million and a subsequent share purchase plan which raised a further $1.5 million, taking the total capital raised to $8.1 million at 30 cents per share.

Funds will be primarily applied towards enhancing the THCs working cRead More – Source

Continue Reading

Australia

Yandal Resources completes shortfall in $3.3 million non-renounceable rights issue

Yandal Resources Ltd (ASX:YRL) has issued the remaining shortfall shares under the 1 for 5 non-renounceable pro-rata rights issue to raise a total of $3.3 million before costs.

On June 12, the company directors announced a pro-rata non-renounceable rights offer to accelerate the Gordons project as well as the Mt McClure project in Western Australia.

Under the rights issue, eligible shareholders were offered the opportunity to acquire one new share for every five shares held at the record date on June 17 at an issue price of 25 cents per new share.

A total of 1.32 million shortfall shares have now been issued for $330,000

Exploration well-funded[hhmc]
The company plans to progress the feasibility study at its Flushing Meadows prospect at the Ironstone Well Project in the September quarter.

Exploration will also continue at the Gordons Dam prospect.

Yandal is well funded for drill programs which were postponed in the June quarter and will be completed in the September quarter.

The..

Yandal Resources Ltd (ASX:YRL) has issued the remaining shortfall shares under the 1 for 5 non-renounceable pro-rata rights issue to raise a total of $3.3 million before costs.

On June 12, the company directors announced a pro-rata non-renounceable rights offer to accelerate the Gordons project as well as the Mt McClure project in Western Australia.

Under the rights issue, eligible shareholders were offered the opportunity to acquire one new share for every five shares held at the record date on June 17 at an issue price of 25 cents per new share.

A total of 1.32 million shortfall shares have now been issued for $330,000

Exploration well-funded


The company plans to progress the feasibility study at its Flushing Meadows prospect at the Ironstone Well Project in the September quarter.

Exploration will also continue at the Gordons Dam prospect.

Yandal is well funded for drill programs which were postponed in the June quarter and will be completed in the September quarter.

These include:

  • 21 AC holes for 2,500 metres at the Flushing Meadows North prospect;
  • 6 AC holes for 720 metres at the Flushing Meadows South prospect;
  • 3 RC holes for 200 metres Read More – Source
Continue Reading

Australia

Nanoveu in back-to-back trading halts ahead of capital raising news

Nanoveu Ltd (ASX:NVU) has been granted back-to-back trading halts by the ASX pending a capital raising announcement.

The trading halt will be in place until the announcement is made or the start of normal ASX trading on Friday, August 7, whichever occurs sooner.

Distribution agreements [hhmc]
Nanoveu recently signed distribution agreements for its antiviral protection products for the Thai and Malaysian markets with Sanyo Trading Company Ltd.

Through these agreements, Sanyo will look to leverage its extensive contacts in the Asia-Pacific region to distribute several Nanoveus products to groups including hospitals, banks, schools and shopping malls.

Nanoveu will ship its business to business (B2B) rolls of antiviral film – to be applied to an increasing number of surfaces – in addition to its consumer-focused antiviral mobile phone cases and doorRead More – Source

[contf]
[contfnew]

Proactiveinvestors
[contfnewc]
[contfnewc]

Nanoveu Ltd (ASX:NVU) has been granted back-to-back trading halts by the ASX pending a capital raising announcement.

The trading halt will be in place until the announcement is made or the start of normal ASX trading on Friday, August 7, whichever occurs sooner.

Distribution agreements


Nanoveu recently signed distribution agreements for its antiviral protection products for the Thai and Malaysian markets with Sanyo Trading Company Ltd.

Through these agreements, Sanyo will look to leverage its extensive contacts in the Asia-Pacific region to distribute several Nanoveus products to groups including hospitals, banks, schools and shopping malls.

Nanoveu will ship its business to business (B2B) rolls of antiviral film – to be applied to an increasing number of surfaces – in addition to its consumer-focused antiviral mobile phone cases and doorRead More – Source

Continue Reading

Trending